Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Sarcoma 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 25Lymphoma, Follicular 24Multiple Myeloma 22Lymphoma, B-Cell, Marginal Zone 21Leukemia 21Lymphoma, Non-Hodgkin 19Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Hematologic Neoplasms 16Waldenstrom Macroglobulinemia 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 12Congenital Abnormalities 11Burkitt Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 10Mycosis Fungoides 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Sezary Syndrome 8Recurrence 8Hodgkin Disease 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Plasma Cell 6Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6

Interventions

Leucovorin 4venetoclax 3Specimen Handling 3Fluorouracil 3Doxorubicin 3Cytarabine 3Cyclophosphamide 3Bevacizumab 3trametinib 2pembrolizumab 2dabrafenib 2Taxes 2Sorafenib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-2 2Gemcitabine 2Daunorubicin 2Carboplatin 2Bortezomib 2Biopsy 2Azacitidine 2Albumin-Bound Paclitaxel 2vactosertib 1temsirolimus 1ruxolitinib 1romidepsin 1regorafenib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Bortezomib × Other hematologic neoplasm × Clear all
NCT00720785 2026-05-07

Natural Killer Cells and Bortezomib to Treat Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡